Karyopharm Therapeutics Inc. 8-K

What Happened
Karyopharm Therapeutics, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025 in a press release dated February 12, 2026, and confirmed it will hold a previously announced, publicly available conference call to discuss those results and other company updates. The press release is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Filing date: February 12, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Reporting period: fourth quarter and full year ended December 31, 2025.
• Press release furnished as Exhibit 99.1 to this Form 8-K (Item 9.01(d)).
• Disclosure is furnished, not “filed,” and therefore is not subject to Section 18 liabilities or automatically incorporated by reference into other filings unless expressly stated.

Why It Matters
Earnings releases and accompanying conference calls provide the latest financial results and management commentary that investors use to assess company performance, trends in revenue and expenses, and near-term expectations. Retail investors should review the Exhibit 99.1 press release and consider listening to the conference call/webcast for management’s discussion and any guidance or operational updates. Note the company’s legal statement that this furnished material is not being treated as “filed” for certain regulatory liability and incorporation purposes.